NeoTX Therapeutics got the go-ahead from the FDA for its IND application for naptumomab estafenatox (NAP). NAP is the company’s lead Tumor Targeted Superantigen (TTS) molecule, which binds a genetically engineered bacterial determinant to the tumor surface while at the same time activating and expanding tumor specific immune cells.

Credit: BioSpace.com